FDA Declares Pox On Both Houses In Enforcement Letters For Curosurf, Infasurf
This article was originally published in The Pink Sheet Daily
Executive Summary
In separate “notice of violation” letters issued Oct. 31 but posted several days apart, FDA rejected superiority claims on the part of Cornerstone Therapeutics and Ony for their respiratory distress syndrome drugs.
You may also be interested in...
Atralin Acne Gel Awarded “A+” In Valeant Ad, But FDA Sends Promo To Back Of The Class
A clever marketing graphic is dinged because it comes in the context of unjustified superiority claims.
Copaxone Promos Can’t List Risks Product Doesn’t Have, Especially Incorrectly, FDA Warns
The first warning letter of the year from FDA’s Office of Prescription Drug Promotion goes to Teva for web pages and materials displayed at a medical conference that overstated the safety and efficacy of its MS drug Copaxone.
DDMAC To Cornerstone: Zyflo CR Promotions Need Current Safety Labeling
An FDA advertising violation letter for Cornerstone Therapeutics' asthma therapy Zyflo CR should serve to remind industry that providing outdated safety labeling with promotions is a sure way to draw the agency's regulatory scrutiny